CorMedix (CRMD) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.29
- Estimate
- $0.24
- Surprise
- +21.9%
- Revenue (period 2026-06-30)
- $101.9M
- Score today
- 7.1/10
Revenue source: xbrl.
How the report landed
CorMedix (CRMD) beat the $0.24 estimate with diluted EPS of $0.29 — a large 21.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRMD Buy (Wait) at 7.1/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +21.9% surprise compares with a +17.3% four-quarter average. Next scheduled report: 2026-11-16.
What supports the rating
- Strong earnings beat streak (3/4)
- Strong overall score: 7.1/10
What argues against it
- Concentration risk — Customer: top three customers (79.0%)
- Earnings expected to decline ~84% (cyclical peak)
- Elevated risk factors
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.20
- Entry target
- $8.47
- Price target
- $13.40
- Stop
- $7.55
- Upside to target
- +63.4%
- Reward-to-risk
- 4.7:1
Forward estimates sit below the trailing run-rate (23.4× forward vs 3.8× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
CRMD at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $639.1M
- P/E (fwd)
- 23.4
- P/E (ttm)
- 3.8
- 52-week range
- $6.13–$14.96
- Off 52-week high
- 45.2%
- RSI (14)
- 59
- Volume vs avg
- 1.02×
- Score today
- 7.1/10